Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

Abstract The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report wa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuluan Li, Pei Zhang, Tianyu Wang, Jie Wang, Jianchun Duan
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	ALK brigatinib chemotherapy lung squamous cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0971c80435b5462b91fbf1f547730466
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0971c80435b5462b91fbf1f547730466
record_format	dspace
spelling	oai:doaj.org-article:0971c80435b5462b91fbf1f5477304662021-12-02T02:34:55ZBrigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report1759-77141759-770610.1111/1759-7714.14133https://doaj.org/article/0971c80435b5462b91fbf1f5477304662021-12-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14133https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK‐positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first‐line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.Shuluan LiPei ZhangTianyu WangJie WangJianchun DuanWileyarticleALKbrigatinibchemotherapylung squamous cell carcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 23, Pp 3273-3276 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ALK brigatinib chemotherapy lung squamous cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	ALK brigatinib chemotherapy lung squamous cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shuluan Li Pei Zhang Tianyu Wang Jie Wang Jianchun Duan Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
description	Abstract The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK‐positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first‐line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.
format	article
author	Shuluan Li Pei Zhang Tianyu Wang Jie Wang Jianchun Duan
author_facet	Shuluan Li Pei Zhang Tianyu Wang Jie Wang Jianchun Duan
author_sort	Shuluan Li
title	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_short	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_full	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_fullStr	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_full_unstemmed	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_sort	brigatinib treated alk positive lung squamous cell carcinoma after failed chemotherapy: a case report
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/0971c80435b5462b91fbf1f547730466
work_keys_str_mv	AT shuluanli brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport AT peizhang brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport AT tianyuwang brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport AT jiewang brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport AT jianchunduan brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport
_version_	1718402326989897728

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

Ejemplares similares